Can a new injection tame prostate cancer by cutting testosterone?
Disease control
Completed
This phase 3 trial is testing an investigational drug called DKF-MA102 (leuprorelin acetate) in men with advanced prostate cancer. The goal is to see if two injections, given 12 weeks apart, can safely lower testosterone levels to a target range, which may help control the cancer…
Phase: PHASE3 • Sponsor: Dongkook Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC